Compound information
- Natural Products
- ZC138813
- Molecular Formula
- C21H31N5O6
- Molecular Weight
- 449.227433712 g/mol
- Structure
-
- IUPAC Name
- benzyl N-[2-[[2-[[(1R)-2-[[(1R,2S)-1-carbamoyl-2-methyl-butyl]amino]-1-methyl-2-oxo-ethyl]amino]-2-oxo-ethyl]amino]-2-oxo-ethyl]carbamate
- InChI
- InChI=1S/C21H31N5O6/c1-4-13(2)18(19(22)29)26-20(30)14(3)25-17(28)11-23-16(27)10-24-21(31)32-12-15-8-6-5-7-9-15/h5-9,13-14,18H,4,10-12H2,1-3H3,(H2,22,29)(H,23,27)(H,24,31)(H,25,28)(H,26,30)/t13-,14+,18+/m0/s1
- InChI Key
- NCZGUWKJUIKIAT-PMUMKWKESA-N
- SMILES
- CC[C@H](C)[C@@H](NC(=O)[C@@H](C)NC(=O)CNC(=O)CNC(=O)OCc1ccccc1)C(N)=O
- Source
- ZINC000006821408
Warheads
- Carbamate
-
ADMET Property
Physicochemical Property
Property | Value | Property | Value |
---|---|---|---|
Heavy Atom Count | 32 | Ring Count | 1 |
Heteroatom Count | 11 | Rotatable Bond Count | 12 |
Hydrogen Bond Acceptor Count | 6 | Hydrogen Bond Donor Count | 5 |
Topological Polar Surface Area | 168.72 Å2 | LogP | 0.723 |
LogS | -2.846 | LogD | 1.098 |
Absorption
Property | Value | Property | Value |
---|---|---|---|
Pgp inhibitor | 0.005 | Pgp substrate | 0.995 |
HIA | 0.08 | F20 % | 0.564 |
F30 % | 0.0 | Caco-2 | -5.641 |
MDCK | -5.63 |
Distribution
Property | Value | Property | Value |
---|---|---|---|
BBB Penetration | 0.344 | PPB | 63.347 |
VD | 0.26 | Fu | 0.63 |
Metabolism
Property | Value | Property | Value |
---|---|---|---|
CYP1A2 inhibitor | 0.001 | CYP1A2 substrate | 0.567 |
CYP2A6 substrate | 0.322 | CYP2B6 substrate | 0.466 |
CYP2C19 inhibitor | 0.355 | CYP2C19 substrate | 0.767 |
CYP2C8 substrate | 0.531 | CYP2C9 inhibitor | 0.034 |
CYP2C9 substrate | 0.983 | CYP2D6 inhibitor | 0.005 |
CYP2D6 substrate | 0.595 | CYP2E1 substrate | 0.339 |
CYP3A4 inhibitor | 0.032 | CYP3A4 substrate | 0.999 |
Excretion
Property | Value | Property | Value |
---|---|---|---|
T1/2 | 0.767 | CL | 3.364 |
Toxicity
Property | Value | Property | Value |
---|---|---|---|
hERG Blockers | 0.009 | Hepatotoxicity | 0.041 |
Mutagenicity | 0.033 | Rat Oral Acute Toxicity | 0.054 |
FDAMDD | 0.024 | Skin Sensitization | 0.011 |
Carcinogenicity | 0.004 | Eye Corrosion | 0.006 |
Eye Irritation | 0.003 | Respiratory Toxicity | 0.031 |
Environmental Toxicity
Property | Value | Property | Value |
---|---|---|---|
Bioconcentration Factors | -2.268 | IGC50 | 1.468 |
LC50FM | 2.149 | LC50DM | 1.643 |
Tox21 Pathway
Property | Value | Property | Value |
---|---|---|---|
NR-AR | 0.232 | NR-AR-LBD | 0.38 |
NR-AhR | 0.002 | NR-Aromatase | 0.028 |
NR-ER | 0.329 | NR-ER-LBD | 0.283 |
NR-PPAR-gamma | 0.249 | SR-ARE | 0.311 |
SR-ATAD5 | 0.34 | SR-HSE | 0.049 |
SR-MMP | 0.006 | SR-p53 | 0.042 |
Similar covalent inhibitors
Similar covalent drugs
No similar covalent drugs found for this compound.